Quantum
Home > Boards > US Listed > Biotechs >

Ra Pharmaceuticals, Inc. (RARX)

RARX RSS Feed
Add RARX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/31/2018 12:53:46 PM - Followers: 1 - Board type: Free - Posts Today: 0

Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge Cambridge, MA 02140 United States 617-401-4060 http://www.rapharma.com Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The company's preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Quantum
RARX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RARX News: ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update 11/07/2018 05:17:00 PM
RARX News: Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update 11/07/2018 04:23:00 PM
RARX News: Quarterly Report (10-q) 11/07/2018 04:16:43 PM
RARX News: Ra Pharmaceuticals to Present at Upcoming Investor Conferences 11/06/2018 07:30:00 AM
RARX News: Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal I... 09/26/2018 07:30:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4   Why is it up today, in volume and price? AnotherInvestor 08/31/18 12:53:46 PM
#3   This seems to be a bit oversold. r clarke 12/11/17 07:29:26 PM
#2   Up and up? AD2000 05/15/17 09:32:14 PM
#1   RARX bullish 22.82 stocktrademan 04/16/17 04:04:12 PM
PostSubject